What is it about?
A number of patients with thyroid cancer are now treated by lobectomy. As one thyroid lobe remains in site and produce significant amounts of thyroglobulin, measurement of circulating thyroglobulin is unreliable in such patients.
Featured Image
Read the Original
This page is a summary of: Is thyroglobulin a reliable biomarker of differentiated thyroid cancer in patients treated by lobectomy? A systematic review and meta-analysis, Clinical Chemistry and Laboratory Medicine (CCLM), April 2022, De Gruyter,
DOI: 10.1515/cclm-2022-0154.
You can read the full text:
Contributors
The following have contributed to this page
